Bacterial infection of the urinary tract and glucose level in patients presented with urinary tract infection in tertiary care hospital, Bihar
Keywords:
UTI, Age group, glycose ureaAbstract
Objectives: This study was to evaluate the bacterial Infection of the Urinary Tract and Glucose Level in patients presented with Urinary Tract Infection in tertiary care hospital. Methods: Sterilized universal (glass) containers were used in collecting early morning midstream urine from patients. Subjects were instructed to void 5mls of Mid-Stream urine. Two hundred early morning, mid-stream urine samples was collected from one hundred patients of urinary tract infection, age between 1 to >60 years with the presence of bacterial species and 2mls of blood was obtained for glucose screening (glycosuria). Testing for Glucose, macroscopic Examinations, and gram stain procedures were performed to all blood samples. Results: Most of the patients 46(23%) were in age group of 51-60 years. 43(21.5%), 39(19.5%) and 35(17.5%) patients were in age group of 21-30 years, 41-50 years and 31-40 years respectively. most predominant isolated bacteria causing urinary tract infection were Escherichia coli 27(32.53%). Other isolated microorganisms were staphylococcus species 18(21.67%), streptococcus species 18(21.67%), 16(19.27%) Klebsiella species and 2(2.41%) proteus spp, pseudomonas spp. Prevalence of UTI was higher in females 49(59.04%) than males 34(40.96%). out of 200 samples, 83(41.5%) samples were infected. Among them, 24(28.92%) had both bacterial infection with glucose.
Downloads
References
Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med, 2002. 113 Suppl 1A: 5s-13s.
J. E. Patterson and V. T. Andriole, “Bacterial urinary tract infec_tions in diabetes,” Infectious Disease Clinics of North America 1997;11(3):735–750.
M. Saleem and B. Daniel, “Prevalence of urinary tract infection among patients with diabetes in Bangalore city,” International Journal of Emerging Sciences 2011;1(2):133–142.
A. Ward, P. Alvarez, L. Vo, and S. Martin, “Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012),” Journal of Medical Economics 2014;17(3):176–183.
Stamm, W. E. & Norrby, S. R. Urinary tract infections: disease panorama and challenges. J. Infect. Dis. 2001;183 (Suppl. 1):S1–S4.
Schappert, S. M. & Rechtsteiner, E. A. Ambulatory medical care utilization estimates for 2007. Vital Health Stat. 2011;13:1–38.
Foxman, B. The epidemiology of urinary tract infection. Nature Rev. Urol. 2010;7:653–660.
Hooton, T. M. Uncomplicated urinary tract infection. New Engl. J. Med. 2012; 366:1028–1037.
Foxman, B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. This paper presents the most recent information about UTIs and their socioeconomic impact. Infect. Dis. Clin. North Am. 2014;28: 1–13.
Hannan, T. J. et al. Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol. Rev. 2012;36:616–648.
Lichtenberger, P. & Hooton, T. M. Complicated urinary tract infections. Curr. Infect. Dis. Rep. 2008; 10:499–504.
Nielubowicz, G. R. & Mobley, H. L. Host–pathogen interactions in urinary tract infection. This review compares the strategies used by two important uropathogens, E. coli and P. mirabilis, the host response to each pathogen, and the current treatments and therapies to prevent UTIs. Nature Rev. Urol 2010; 7: 430–441.
Fisher, J. F., Kavanagh, K., Sobel, J. D., Kauffman, C. A. & Newman, C. A. Candida urinary tract infection: pathogenesis. Clin. Infect. Dis. 2011;52 (Suppl. 6): S437–S451.
Jacobsen, S. M., Stickler, D. J., Mobley, H. L. & Shirtliff, M. E. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin. Microbiol. Rev 2008; 21:26–59.
C. M. Kunin, “Chemoprophylaxis and suppressive therapy in the management of urinary tract infections,” Journal of Antimicrobial Chemotherapy 1994; 33: 51–62.
Fünfstück R, Nicolle LE, Hanefeld M, Naber KG. Urinary tract infection in patients with diabetes mellitus. Clin Nephrol. 2012;77(1):40–48.
Schneeberger C, Kazemier BM, Geerlings SE. Asymptomatic bac_teriuria and urinary tract infections in special patient groups: women with diabetes mellitus and pregnant women. Curr Opin Infect Dis. 2014;27(1):108–114.
Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med. 1997;14(1):29–34.
Yu S, Fu AZ, Qiu Y, Engel SS, Shankar R, Brodovicz KG, et al. Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the US. JDC. 2014;28(5):621–6.
Sharma S, Govind B, Naidu SK, Kinjarapu S, Rasool M. Clinical and laboratory profile of urinary tract infections in type 2 diabetics aged over 60 years. JCDR. 2017;11(4):OC25–8.
Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015; 8:129–36.
S. E. Geerlings, R. P. Stolk, M. J. L. Camps et al., “Asymptomatic bacteriuria may be considered a complication in women with diabetes,” Diabetes Care 2000;23(6):744–749.
L. E. Nicolle, “Urinary tract infections in special populations. diabetes, renal transplant, HIV infection, and spinal cord injury,” Infectious Disease Clinics of North America 2014; 28(1): 91–104.
S. E. Geerlings, R. P. Stolk, M. J. L. Camps, P. M. Netten, T. J. Collet, and A. I. M. Hoepelman, “Risk factors for symptomatic urinary tract infection in women with diabetes,” Diabetes Care 2000; 23,(12):1737–1741.
S. E. Geerlings, “Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment,” International Journal of Antimicrobial Agents 2008; 31(1):54–57.
D. Sauerwein, “Urinary tract infection in patients with neuro_genic bladder dysfunction,” International Journal of Antimicro_bial Agents 2002; 19(6):592–597.
L. E. Nicolle, G. Capuano, A. Fung, and K. Usiskin, “Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor,” Postgraduate Medicine 2014; 126(1):7–17.
K. M. Johnsson, A. Ptaszynska, B. Schmitz, J. Sugg, S. J. Parikh, and J. F. List, “Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin,” Journal of Diabetes and Its Complications 2013;27(5):479–484.
R. James and A. Hijaz, “Lower urinary tract symptoms in women with diabetes mellitus: a current review,” Current Urology Reports 2014; 15(10): 440.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.








